1. Home
  2. BYFC vs RLYB Comparison

BYFC vs RLYB Comparison

Compare BYFC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadway Financial Corporation

BYFC

Broadway Financial Corporation

N/A

Current Price

$11.66

Market Cap

104.4M

Sector

Finance

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$15.80

Market Cap

89.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BYFC
RLYB
Founded
1946
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.4M
89.2M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
BYFC
RLYB
Price
$11.66
$15.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1K
★ 22.0K
Earning Date
07-28-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
0.07
★ 5.64
Revenue
$184,000.00
★ $858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$165.71
★ $2.79
Revenue Growth
18.71
★ 43.00
52 Week Low
$5.51
$0.56
52 Week High
$12.35
$32.54

Technical Indicators

Market Signals
Indicator
BYFC
RLYB
Relative Strength Index (RSI) 63.80 37.68
Support Level $11.76 $7.93
Resistance Level $12.27 $16.89
Average True Range (ATR) 0.14 1.77
MACD 0.06 -0.03
Stochastic Oscillator 100.00 1.91

Price Performance

Historical Comparison
BYFC
RLYB

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: